MarginsXMarginsX
Home › Markets › Health Care › PLUR

Pluri Inc. (PLUR)

PLUR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.04
-0.95% on the day
Market cap
$15.0M
Nano cap
Revenue · 2026
$1.0M
-24.0% on 2025
Net income · 2026
-$23.8M
-2344.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/0001213900-26-098862-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerPLUR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0001158780
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNV

Financials · 2026

LineValue
Revenue$1.0M
Net income-$23.8M
Operating income-$24.9M
Net margin-2344.6%
Operating margin-2454.5%
Revenue growth-24.0%
Cash$3.5M
Total assets$24.9M
P/E (computed)Net income was not positive
P/S (computed)14.7×

Warning signs

Cash runway
2.2 months
$3.5M cash at September 30, 2026
Share count, 1 year
+55.3%
2025-11-11 to 2026-11-11 · +177.3% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$3.5M cash; operating cash flow -$4.7M a quarter.Report 2026-09-30
Shares outstanding14,375,922 (2026-11-11); 9,253,897 a year earlier; 41,480,172 three years earlier. 3y figure adjusted for splits (1-for-8 overall).Cover page 2026-11-11
Reverse splits, 3 years1; latest 1-for-8 on 2024-04-01Source 2024-04-01
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-28
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-07-13
AuditorKesselman & Kesselman C.P.A.s, Haifa, IsraelPCAOB Form AP 2026-09-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
$759K-$10.4M-$4.5M$3.5MNo debt tags$1.5M10-Q 2026-11-12
Q4 2026
2026-06-30
$335K-$5.9M-$4.4M$3.5MNo debt tags$1.0M10-K 2026-09-10
Q3 2026
2026-03-31
$167K-$5.5M-$4.5M$3.4MNo debt tags$1.1M10-Q 2026-05-14
Q2 2026
2025-12-31
$198K-$6.5M-$5.2M$4.7MNo debt tags$1.3M10-Q 2026-02-12
Q1 2026
2025-09-30
$316K-$5.8M-$5.4M$4.3MNo debt tags$1.3M10-Q 2026-11-12
Q4 2025
2025-06-30
$398K-$7.6M-$5.2M$5.9MNo debt tags$1.3M10-K 2026-09-10
Q3 2025
2025-03-31
$427K-$6.1M-$4.3M$8.5M$24.9M$1.0M10-Q 2026-05-14
Q2 2025
2024-12-31
$185K-$3.0M-$4.6M$7.2M$23.8M$678K10-Q 2026-02-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
S-12026-10-06
Latest annual report
ANNUAL REPORT
10-K2026-09-10
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-12
Latest current report
CURRENT REPORT
8-K2026-10-30
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 956 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.3%
1 month+11.7%
3 months-36.7%
Year to date-64.9%
1 year-74.9%
From 52-week high-73.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ABOSAcumen Pharmaceuticals Inc.$0.2160+0.93%$15.6M
ESLAEstrella Immunopharma Inc.$0.3800-26.07%$16.5M
ATYRaTyr Pharma Inc.$5.24-14.17%$13.4M
PASGPassage Bio Inc.$4.13-2.82%$13.3M
JSPRJasper Therapeutics Inc.$11.77-13.96%$13.1M
DYAIDyadic International Inc.$0.3200-2.14%$12.8M
BSEMBioStem Technologies Inc.$0.9601-8.56%$18.4M
BCDABioCardia Inc.$0.7901-4.92%$12.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier